Abstract

Atherosclerosis (AT) is a progressive chronic disease involving lipid accumulation, fibrosis, and inflammation in medium and large-sized arteries, and it is the main cause of cardiovascular disease (CVD). AT is caused by dyslipidemia and mediated by both innate and adaptive immune responses. Despite lipid-lowering drugs have shown to decrease the risk of cardiovascular events (CVEs), there is a significant burden of AT-related morbidity and mortality. Identification of subjects at increased risk for CVE as well as discovery of novel therapeutic targets for improved treatment strategies are still unmet clinical needs in CVD. Microvesicles (MVs), small extracellular plasma membrane particles shed by activated and apoptotic cells have been widely linked to the development of CVD. MVs from vascular and resident cells by facilitating exchange of biological information between neighboring cells serve as cellular effectors in the bloodstream and play a key role in all stages of disease progression. This article reviews the current knowledge on the role of MVs in AT and CVD. Attention is focused on novel aspects of MV-mediated regulatory mechanisms from endothelial dysfunction, vascular wall inflammation, oxidative stress, and apoptosis to coagulation and thrombosis in the progression and development of atherothrombosis. MV contribution to vascular remodeling is also discussed, with a particular emphasis on the effect of MVs on the crosstalk between endothelial cells and smooth muscle cells, and their role regulating the active process of AT-driven angiogenesis and neovascularization. This review also highlights the latest findings and main challenges on the potential prognostic, diagnostic, and therapeutic value of cell-derived MVs in CVD. In summary, MVs have emerged as new regulators of biological functions in atherothrombosis and might be instrumental in cardiovascular precision medicine; however, significant efforts are still needed to translate into clinics the latest findings on MV regulation and function.

Highlights

  • Despite significant advances in prevention, diagnosis, and therapeutic intervention focused on strategies for preventing cardiovascular disease (CVD), coronary artery disease (CAD) remains the leading cause of mortality and morbidity worldwide

  • The present review focuses on MVs, which are formed by budding of the plasma membrane, a releasing process that is driven by calcium-dependent signaling, activity of several enzymes, cytoskeleton remodeling, and externalization of phosphatidylserine (PS)

  • We have demonstrated that tissue factor (TF)-containing endothelial-derived microvesicle (eMV) from microvascular Endothelial cell (EC) interacted via paracrine signaling with other microvascular endothelial cell (mEC) and triggered angiogenesis ex vivo and postischemic collateral vessel growth in vivo [216]

Read more

Summary

INTRODUCTION

Despite significant advances in prevention, diagnosis, and therapeutic intervention focused on strategies for preventing cardiovascular disease (CVD), coronary artery disease (CAD) remains the leading cause of mortality and morbidity worldwide. In a study focused on the effects of LLT on levels of cMV in atherosclerotic patients in primary prevention, we have reported that the plasma of LLT-treated patients presented lower quantity of MVs and lower content of cell surface activation markers than the plasma from untreated patients with the same blood cholesterol levels [255], indicating a direct benefit of LLT with statins in reducing cell membrane shedding, which may have effects in the beneficial protection against AT characteristic of statins by inhibiting MV generation and the triggering of MV-dependent mechanisms These data are in agreement to results pointing out the broader use of statins decreasing inflammation and suppressing MV release, an effect that is not shown neither with ezetimibe alone [259] nor with ezetimibe combined with statins [260]. Abciximab: 250 μg/kg bolus + 12 h 0.125 μg/kg/min Eptifibatide: 180 μg/kg bolus + 18 h 2 μg/kg/min

50 ST-segment elevation patients undergoing percutaneous coronary intervention
CONCLUSION AND FUTURE PERSPECTIVES
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call